-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Mitoxantrone dihydrochloride
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/70476-82-3.gif)
| Category | Orthopoxvirus |
| CAS | 70476-82-3 |
| Description | It is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. Mitoxantrone dihydrochloride is an antiviral, antibacterial, antiprotozoal, immunomodulating and antineoplastic anthraquinone derivative. |
Product Information
| Synonyms | 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthracene-9,10-dione dihydrochloride; DHAQ; CL-232325; CL 232325; CL232325; Novantrone; Mitroxone; Neotalem; Onkotrone; Pralifan; Mitoxantrone 2HCl; Immunex |
| IUPAC Name | 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione;dihydrochloride |
| Molecular Weight | 517.40 |
| Molecular Formula | C22H28N4O6.2HCl |
| Canonical SMILES | C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO.Cl.Cl |
| InChI | InChI=1S/C22H28N4O6.2ClH/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;;/h1-4,23-30H,5-12H2;2*1H |
| InChIKey | ZAHQPTJLOCWVPG-UHFFFAOYSA-N |
| Boiling Point | 805.7°C at 760 mmHg |
| Melting Point | 203-205°C |
| Flash Point | 441.1ºC |
| Purity | >98% |
| Solubility | Soluble in Ethanol (1 mg/mL), Water, DMSO |
| Appearance | Dark Blue to Black Solid |
| Storage | Store at 2-8°C |
| In Vitro | Mitoxantrone dihydrochloride inhibits PKC in a competitive manner with respect to histone H1, and its Ki value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP. Mitoxantrone dihydrochloride (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone dihydrochloride induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone dihydrochloride is due to induction of Apoptosis. Mitoxantrone dihydrochloride shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC50 values of 18 and 196 nM, respectively. |
| In Vivo | Mitoxantrone dihydrochloride (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia. Mitoxantrone dihydrochloride (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma. |
| PSA | 163.18000 |
| Target | Topoisomerase; PKC; Orthopoxvirus; Apoptosis; Endogenous Metabolite |
